To date, this study is the first and most comprehensive systematic review and meta-analysis assessing the safety of GLP-1 RA treatment with respect to esophageal cancer risk in patients with T2DM or obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.